- Revenue Increased by 87 percent to $3.4 million compared to Q3 2015
- Gross profit exceeds 83 percent to approximately $2.8 million compared to Q3 2015
- Third quarter Non-GAAP dilution of $356,000 compared to $459,000 in Q3 2015
- Cash flow increases by $60,000 compared to the Q2 2016 cash flow
About BrainswayBrainsway Ltd./ Brainsway USA is a leader in non-invasive treatments for brain disorders utilizing Deep Transcranial Magnetic Stimulation (Deep TMS). Our unique patented technology was developed in collaboration with the National Institute of Health (NIH) and is FDA and CE cleared to treat patients with depression who are not currently responding to medication. The treatment has been enthusiastically supported by many academic communities and is widely covered by most insurance payers. For more information, please visit www.brainsway.com.Forward-Looking StatementsThis press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
Media Contact:Megan Vandenbosmegan@antennagroup.com201-465-8019